Comprehensive Medicinal Chemistry II

1st Edition



  • Walter Moos
    • Print ISBN 9780080445151


    Strategy and project management is very important in the pharmaceutical and biotechnology industries as it can take a decade and over a billion dollars to develop a successful drug. This comprehensive volume presents academic, industry and other complementary viewpoints on the drug research process with many illustrative examples, anecdotes and representative case studies. Experts evaluate the strengths and weaknesses of old and new methods, the crossroads of tactics and strategy and market forces. Project management chapters highlight decisions that must be made along the drug discovery pathway and investigate outsourcing, licensing, innovation and managing scientists. The volume concludes with some case studies so that readers can examine practical applications of strategy and project management applied to real life examples.

    Key Features

    * valuable content available from May 2009 as an individual volume
    * separate volumes will appeal to a wider chemistry, biochemistry and medicinal audience
    * priced for individual researcher as well as library purchase


    For students and researchers in chemistry, biochemistry, medicinal chemistry and pharmacology and scientists working in the pharmaceutical industries.

    Table of Contents

    Volume 2 Strategy and Drug Research
    2.01 The Intersection of Strategy and Drug Research
    2.02 An Academic Perspective
    2.03 An Industry Perspective
    Organizational Aspects and Strategies for Drug Discovery and Development
    2.04 Project Management
    2.05 The Role of the Chemical Development, Quality, and Regulatory Affairs Teams in Turning a Potent Agent into a Registered Product
    2.06 Drug Development
    2.07 In-House or Out-Source
    2.08 Pharma versus Biotech: Contracts, Collaborations, and Licensing
    2.09 Managing Scientists, Leadership Strategies in Science
    2.10 Innovation (Fighting against the Current)
    2.11 Enabling Technologies in Drug Discovery: The Technical and Cultural Integration of the New with the Old
    2.12 How and Why to Apply the Latest Technology
    2.13 How and When to Apply Absorption, Distribution, Metabolism, Excretion, and Toxicity
    2.14 Peptide and Protein Drugs: Issues and Solutions
    2.15 Peptidomimetic and Nonpeptide Drug Discovery: Receptor, Protease, and Signal Transduction Therapeutic Targets
    2.16 Bioisosterism
    2.17 Chiral Drug Discovery and Development – From Concept Stage to Market Launch
    2.18 Promiscuous Ligands
    2.19 Diversity versus Focus in Choosing Targets and Therapeutic Areas
    2.20 G Protein-Coupled Receptors
    2.21 Ion Channels – Voltage Gated
    2.22 Ion Channels – Ligand Gated
    2.23 Phosphodiesterases
    2.24 Protein Kinases and Protein Phosphatases in Signal Transduction Pathways
    2.25 Nuclear Hormone Receptors
    2.26 Nucleic Acids (Deoxyribonucleic Acid and Ribonucleic Acid)
    2.27 Redox Enzymes


    No. of pages:
    © 2007
    Elsevier Science
    Print ISBN:

    About the author

    Walter Moos

    Dr. Walter Moos joined the independent nonprofit SRI International (founded in 1946 by Stanford University and formerly known as Stanford Research Institute) in 2005 as Vice President and head of the Biosciences Division. In 2015, he was named President of SRI Biosciences. This unique organization has nearly doubled in size in recent years to more than 300 people, integrating all of the resources necessary to take projects from idea to IND and beyond. Applying innovation best practices, SRI Biosciences integrates basic biomedical research with drug and diagnostics discovery and preclinical and clinical development, with clients and partners around the world – like a university, biotech venture, and contract services organization all rolled into one. Moos was also responsible for managing corporate Information Technology Services at SRI from 2011-2014. During his career, Moos and his teams have made significant contributions to all stages of pharmaceutical R&D, from early stage research on therapeutics and diagnostics to marketed products. Prior to SRI, he was Chairman and Chief Executive Officer of MitoKor Inc. (became Migenix) and a Vice President of R&D at Chiron Corp. (became Novartis) and the Parke-Davis Pharmaceutical Research Division of Warner-Lambert Co. (became Pfizer). His teams have helped advance a number of drugs and biologics from research to market, supported by Alta Partners, the Gates Foundation, the National Institutes of Health, and Pfizer, among many others. He has served on about 20 business and scientific boards, both not-for-profit and for-profit, including the Biotechnology Industry Organization (BIO), the Critical Path Institute, Keystone Symposia, Oncologic (Aduro), Onyx (Amgen), and Rigel. He has served as an advisor and committee member for academic, government, and investor groups, including the University of Michigan, the National Academy of Sciences, and Red Abbey Venture Partners. He has co-founded several scientific journals, co-edit